US Patent

US12533408 — Treatment regimen for the treatment of autoimmune disorders

Method of Use · Assigned to Merck Patent GmbH · Expires 2041-09-10 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a treatment regimen for the treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient.

USPTO Abstract

A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections.

Drugs covered by this patent

Leustatin (CLADRIBINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4395`	—	Leustatin

Patent Metadata

Patent number: US12533408
Jurisdiction: US
Classification: Method of Use
Expires: 2041-09-10
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.